OBJECTIVE: Little is known about the patterns of use of initial kidney replacement therapies among patients with lupus nephritis (LN) end-stage renal disease (ESRD). We aimed to identify sociodemographic and clinical factors associated with variation in initial kidney replacement therapies among LN ESRD patients. METHODS: Patients with incident LN ESRD (1995-2006) were identified in the US Renal Data System. Age, sex, race, ethnicity, medical insurance, employment status, residential region, clinical factors, and comorbidities were considered as potential predictors of ESRD treatment choice, i.e., peritoneal dialysis (PD), hemodialysis (HD), or preemptive kidney transplantation in age-adjusted and multivariable-adjusted logistic regression analyses. RESULTS: Of the 11,317 individuals with incident LN ESRD, 82.0% initiated HD, 12.2% initiated PD, and 2.8% underwent preemptive kidney transplantation. Receiving initial PD was significantly associated with earlier calendar year, female sex, higher albumin and hemoglobin levels, and lower serum creatinine levels. African Americans (versus whites), Medicaid beneficiaries and those with no health insurance (versus private insurance), and those unemployed (versus employed) had significantly reduced PD initiation. Comorbidities including congestive heart failure, peripheral vascular disease, and the inability to ambulate were also associated with decreased PD. Many sociodemographic and clinical factors favoring PD were associated with preemptive kidney transplant (versus dialysis) as well. CONCLUSION: Few patients with LN ESRD receive initial PD or preemptive kidney transplantation. Race, ethnicity, employment, and medical insurance type are strongly associated with initial kidney replacement therapy choice. Future studies need to investigate the appropriateness of sociodemographic and clinical variation and the comparative effectiveness of kidney replacement therapies for LN ESRD.
OBJECTIVE: Little is known about the patterns of use of initial kidney replacement therapies among patients with lupus nephritis (LN) end-stage renal disease (ESRD). We aimed to identify sociodemographic and clinical factors associated with variation in initial kidney replacement therapies among LN ESRDpatients. METHODS:Patients with incident LN ESRD (1995-2006) were identified in the US Renal Data System. Age, sex, race, ethnicity, medical insurance, employment status, residential region, clinical factors, and comorbidities were considered as potential predictors of ESRD treatment choice, i.e., peritoneal dialysis (PD), hemodialysis (HD), or preemptive kidney transplantation in age-adjusted and multivariable-adjusted logistic regression analyses. RESULTS: Of the 11,317 individuals with incident LN ESRD, 82.0% initiated HD, 12.2% initiated PD, and 2.8% underwent preemptive kidney transplantation. Receiving initial PD was significantly associated with earlier calendar year, female sex, higher albumin and hemoglobin levels, and lower serum creatinine levels. African Americans (versus whites), Medicaid beneficiaries and those with no health insurance (versus private insurance), and those unemployed (versus employed) had significantly reduced PD initiation. Comorbidities including congestive heart failure, peripheral vascular disease, and the inability to ambulate were also associated with decreased PD. Many sociodemographic and clinical factors favoring PD were associated with preemptive kidney transplant (versus dialysis) as well. CONCLUSION: Few patients with LN ESRD receive initial PD or preemptive kidney transplantation. Race, ethnicity, employment, and medical insurance type are strongly associated with initial kidney replacement therapy choice. Future studies need to investigate the appropriateness of sociodemographic and clinical variation and the comparative effectiveness of kidney replacement therapies for LN ESRD.
Authors: Wolfgang C Winkelmayer; Robert J Glynn; Murray A Mittleman; Raisa Levin; Joseph S Pliskin; Jerry Avorn Journal: J Am Soc Nephrol Date: 2002-09 Impact factor: 10.121
Authors: J Craig Longenecker; Josef Coresh; Michael J Klag; Andrew S Levey; Alice A Martin; Nancy E Fink; Neil R Powe Journal: J Am Soc Nephrol Date: 2000-03 Impact factor: 10.121
Authors: Karen H Costenbader; Amrita Desai; Graciela S Alarcón; Linda T Hiraki; Tamara Shaykevich; M Alan Brookhart; Elena Massarotti; Bing Lu; Daniel H Solomon; Wolfgang C Winkelmayer Journal: Arthritis Rheum Date: 2011-06
Authors: Paul Roderick; Chris Jones; Nick Drey; Sara Blakeley; Premila Webster; Jonathan Goddard; Sue Garland; Linda Bourton; Juan Mason; Charlie Tomson Journal: Nephrol Dial Transplant Date: 2002-07 Impact factor: 5.992
Authors: Tzu-Chieh Lin; Michael F Marmor; Medha Barbhaiya; Hongshu Guan; Sarah K Chen; Candace H Feldman; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2018-11 Impact factor: 4.794
Authors: Jose A Gómez-Puerta; Candace H Feldman; Graciela S Alarcón; Hongshu Guan; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2015-10 Impact factor: 4.794
Authors: Kevin F Erickson; Jenny I Shen; Bo Zhao; Wolfgang C Winkelmayer; Glenn M Chertow; Vivian Ho; Jay Bhattacharya Journal: J Am Soc Nephrol Date: 2019-12-19 Impact factor: 10.121
Authors: Gabriel Contreras; Javier Pagan; Ruchir Chokshi; Sharad Virmani; Jorge M Diego; Patricia Byers; Tamara Isakova; Jair Munoz Mendoza; Ali Nayer; Jose Roberto Contreras; Gabriel Panama; Oliver Lenz; Maria Carpintero; Timothy Muchayi; David Roth Journal: Clin J Am Soc Nephrol Date: 2014-09-04 Impact factor: 8.237
Authors: Michelle M O'Shaughnessy; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer Journal: Nephrol Dial Transplant Date: 2015-11-25 Impact factor: 5.992
Authors: José A Gómez-Puerta; Sushrut S Waikar; Daniel H Solomon; Jun Liu; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader Journal: J Clin Cell Immunol Date: 2013-12-01
Authors: Katherine P Pryor; Medha Barbhaiya; Karen H Costenbader; Candace H Feldman Journal: Rheum Dis Clin North Am Date: 2020-10-29 Impact factor: 2.670